Zhejiang Hisun Pharmaceutical Subsidiary Gets Good Manufacturing Practice Certificate for Anti-Acne Antibiotic

MT Newswires Live12-04

Authorities in Jiangsu, China, granted Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Hisun Pharmaceutical Nantong a good manufacturing practice certification, according to a Thursday filing with the Shanghai bourse.

The inspection covered the minocycline hydrochloride production lines, it said.

Minocycline hydrochloride is an antibiotic indicated for use against Staphylococcus, Streptococcus, Pneumococcus, Neisseria gonorrhea, Shigella, Escherichia coli, Klebsiella, Proteus, Pseudomonas aeruginosa, Treponema pallidum, and Chlamydia, the filing said.

It is used to treat acne vulgaris, according to the Mayo Clinic.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment